Skip to main content
Premium Trial:

Request an Annual Quote

Silence Issued Japanese Patent on RNAi Technology

Premium

Silence Therapeutics said this week that it has been issued a Japanese patent covering its core RNAi technology.

The patent, No. 4,705,370, is entitled “Further Novel Forms of Interfering RNA Molecules,” and claims siRNAs containing proprietary 2’-O-methyl structures.

“The ability to expand our strong RNAi patent portfolio into a large pharmaceutical market such as Japan represents … [a] success in our proactive ongoing intellectual property strategy,” Silence CEO Philips Haworth said in a statement.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.